775294-71-8|AC-73|AC-73|-范德生物科技公司

AC-73

NMR下载 COA and HPLC MSDS下载
names：
AC-73
CAS号：
775294-71-8
MDL Number：
MF(分子式)： C21H21NO2 MW(分子量)： 319.4
EINECS: Reaxys Number:
Pubchem ID:2989791 Brand:BIOFOUNT

AC-73(775294-71-8)是 Cluster of Differentiation 147 (CD147) 的第一种特定的口服生物利用的抑制剂，可特异性破坏 CD147 的二聚化 (结合位点在 CD147 的 N 端 IgC2 域中包括 Glu64 和 Glu73)，从而抑制 CD147/ERK1/2/STAT3/MMP-2 途径，并抑制肝癌细胞的运动和侵袭。AC-73 还是一种抗增殖药，也是白血病细胞自噬的诱导剂。

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM002116-10mg	10mg	99%	¥ 2140.00	¥ 2140.00		2-3天	- +	¥ 0.00
YZM002116-5mg	5mg	99%	¥ 1160.00	¥ 1160.00		2-3天	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	AC-73(775294-71-8)
英文别名	AC-73,775294-71-8
CAS号	775294-71-8
SMILES	OC(CNCC1=CC=C(C2=CC=CC=C2)C=C1)C3=CC=CC(O)=C3
Inchi	InChI=1S/C21H21NO2/c23-20-8-4-7-19(13-20)21(24)15-22-14-16-9-11-18(12-10-16)17-5-2-1-3-6-17/h1-13,21-24H,14-15H2
InchiKey	UECKKYNEEBRMIL-UHFFFAOYSA-N
分子式 Formula	C21H21NO2
分子量 Molecular Weight	319.4
闪点 FP	171.1±20.7 °C
熔点 Melting point	NA
沸点 Boiling point	551.8±50.0 °C at 760 mmHg
Polarizability极化度	38.3±0.5 10-24cm3
密度 Density	1.2±0.1 g/cm3
蒸汽压 Vapor Pressure	0.0±1.6 mmHg at 25°C
溶解度Solubility
性状	白色至灰白色固体粉末
储藏条件 Storage conditions	storage at -4℃ (1-2weeks), longer storage period at -20℃ (1-2years)

AC-73(CAS:775294-71-8)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

产品说明	AC-73(cas:775294-71-8) 是Cluster of Differentiation 147 (CD147)的第一种特定的口服生物利用的抑制剂
Introduction	AC3 is a first specific, orally active inhibitor of cluster of differentiation 147 (CD147), which specifically disruptsCD147dimerization, thereby mainly suppressing theCD147/ERK1/2/STAT3/MMP pathways.
Application1	AC3 is also an antiroliferative drug and an inducer of autophagyin leukemic cells.
Application2	AC3 inhibits the motility and invasion of hepatocellular carcinoma cells.
Application3

IC₅₀ & Target	CD147
In Vitro	※ AC-73 (5-10 μM; 24 hours; SMMC-7721 and Huh-7 cells) treatment significantly decreases the migration ability of SMMC-7721 and Huh-7 cells in a dose-dependent manner and decreases the invasion of two HCC cells in a dose-dependent manner at 24 hours. AC-73 treatment reduces HCC metastases. There are no obvious effects on cell viability when two HCC cells are treated with AC-73 at a maximum concentration of 20 μM. The possible binding sites of AC-73 on CD147 included Glu64 and Glu73 in the N-terminal IgC2 domain, which two residues are located in the dimer interface of CD147. ※ AC-73 (5-10 μM; 24 hours; SMMC-7721 cells) treatment could significantly inhibit both MMP-2 and MMP-9 mRNA expression at the concentration of 10 μM, especially MMP-2, but no obvious effect on MMP-1, MMP-3, MMP-7, MMP-11 nor MMP-13. AC-73 could dose dependently reduce the expression of MMP-2 mRNA level and secretion of the protein level using RT-qPCR analysis and gelatin zymography experiments. ※ AC-73 (5-20 μM; 6 hours; SMMC-7721 cells) treatment dose-dependently suppresses the phosphorylation of ERK1/2 and STAT3.
	Cell Line:	SMMC-7721 cells
	Concentration:	5 μM or 10 μM
	Incubation Time:	24 hours
	Result:	Significantly inhibited both MMP-2 and MMP-9 mRNA expression at the concentration of 10 μM. Dose dependently reduced the expression of MMP-2 mRNA level and secretion of the protein level using RT-qPCR analysis and gelatin zymography experiments.
In Vivo	AC-73 (25-50 mg/kg; for 4 weeks; Male BALB/c nu/nu mice) treatment significantly decreases the incidence of metastatic foci in nude mice. AC-73 inhibits the phosphorylation of ERK1/2 and STAT3 in a dose-dependent manner. MMP-2 is also reduced by AC-73. AC-73 could not inhibit tumor cell proliferation in vivo.
	Animal Model:	Male BALB/c nu/nu mice (4-6 weeks) with SMMC-7721 cells
	Dosage:	25 mg/kg, 50 mg/kg
	Administration:	Injected; daily; for 3 weeks
	Result:	Significantly decreased the incidence of metastatic foci in nude mice. Inhibited the phosphorylation of ERK1/2 and STAT3 in a dose-dependent manner. MMP-2 was also reduced.

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护